Ann: CardieX Files Form F-1 to Dual List on US Nasdaq Exchange, page-3

Yep, no price per share or $ raise amount yet, but here is a couple of nice segments below from the Form F-1 filing for CDX

Our Outlook

As both the patient monitoring and the clinical trials markets increasingly rely on the remote collection of vital signs such as blood pressure, we believe that our focus on creating cloud-enabled devices under the CONNEQT brand will enable us to commercialize a compelling solution for those markets.

While the market for remote patient monitoring, both in healthcare and clinical trial settings, is highly competitive with frequent new entrants, and we have no history of marketing or sales execution with our CONNEQT Products, we believe the clinical evidence that have been generated from our SphygmoCor technology over the past two decades enables us to create a unique and competitive value proposition.

Although we also recognize there may be some challenges to remote vital signs collection, whether as part of a remote patient monitoring program or decentralized trial, we believe the benefits outweigh such challenges.

For example, although there is an advantage to our patients having access to a smartphone with either WiFi or a cellular data connection to access the internet, our products do not require such access.

The health data collected by our devices is stored on the device, making it so a smartphone is not required to support the product’s functionality and the collection of data.

Access to a smartphone with internet access would also enable secure remote transmission of the health data to a patient’s physician or care provider.

However, a patient can download all data at a doctor’s office if he or she does not have access to a smartphone with internet connection.

Similarly, although patients using our products outside of their doctor’s offices need to learn how to properly use our products, we believe that they can learn how to do so as the usage instructions are similar to home blood pressure monitors and fitness trackers currently available on the market.

Furthermore, our user manuals include graphical illustrations to ensure that the instructions are easy to follow.

Our Growth Strategies

Our goal is to be the leading provider of home, wearable, healthcare, clinical trial, and remote patient monitoring solutions for common health disorders related to high blood pressure including hypertension, CVD, Alzheimer’s disease, chronic kidney disease (CKD), and other major vascular health conditions.

To achieve our growth plan, we expect to employ the following growth strategies:

• Expand CONNEQT through our existing partner ecosystem. We plan to capture a significant untapped opportunity with CONNEQT by incorporating the SphygmoCor vascular biosensing technology in wearables, in-clinic patient monitoring solutions for general practitioners, remote patient monitoring, and decentralized clinical trials.
• Regulatory progress. We are the only company with an FDA-cleared technology capable of providing a non-invasive cBP reading with full pulse waveform output features and analysis in all adult populations.

CONNEQT Pulse is the fourth generation of our device to receive FDA clearance and FDA clearance of the CONNEQT Band is anticipated in the first quarter of calendar year 2024.

However, there is no guarantee that the FDA will grant clearance to the CONNEQT Band or that it will do so on the timeline currently indicated.

• Building a health ecosystem and brand. In addition to our SphygmoCor vascular health parameters, the CONNEQT Band will also be a comprehensive lifestyle wearable incorporating a suite of features and health insights, derived from a wrist-based PPG sensor, thereby enabling users to obtain a complete 360-degree view of their health and fitness status.

When paired with the CONNEQT App, the CONNEQT Band will continuously track users’ heart health, support 24/7 practitioner monitoring and apply advanced intelligent analytics (our Arty Heart Health platform) to evaluate their health data in order to provide actionable insights regarding their unique vascular and health status.

• Expand payor coverage and reimbursement. A key component in ensuring whether the appropriate payment amount is received for physician and other services, including those procedures using our products, is the existence of a Current Procedural Terminology (CPT) code to describe the procedure in which the product is used. To receive payment, health care practitioners must submit claims to insurers using these codes for payment for medical services.

CPT codes are assigned, maintained and annually updated by the American Medical Association and its CPT Editorial Board.

• Continue to scale our operations in the United States to accelerate the growth of ATCOR and CONNEQT Products. We expect to continue to scale our business in the United States by hiring additional U.S.-based managers as well as sales and marketing and end-user support personnel to enhance our ability to acquire customers and retain and grow these relationships.

We expect that by expanding our U.S. team, we will acquire additional commercial expertise that will enable us to grow our customer and revenue base by continuing to cultivate satisfied customers and building key relationships with U.S. medical societies, which we believe will position us to create the value and tools required to win in an evolving competitive healthcare landscape.

• Growth through partnerships and acquisitions.

While we continue to accelerate our internal organic sales growth we will also monitor opportunities to expand our business through select partnerships and acquisitions, especially as we look to drive value through a more vertically integrated product offerings in our target markets.